Hänggi, D., Etminan, N., Steiger, H., Mayer, S. A., & Macdonald, R. L. (2017). Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (Newton [nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage]). Stroke, 48(1), . https://doi.org/10.1161/STROKEAHA.116.014250
Chicago-Zitierstil (17. Ausg.)Hänggi, Daniel, Nima Etminan, Hans-Jakob Steiger, Stephan A. Mayer, und Robert Loch Macdonald. "Randomized, Open-label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (Newton [nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])." Stroke 48, no. 1 (2017). https://doi.org/10.1161/STROKEAHA.116.014250.
MLA-Zitierstil (9. Ausg.)Hänggi, Daniel, et al. "Randomized, Open-label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (Newton [nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])." Stroke, vol. 48, no. 1, 2017, https://doi.org/10.1161/STROKEAHA.116.014250.